Kurt Rote

Kurt Rote is a prominent figure in the biotechnology sector, currently serving as a Board Member and Founder at KaliVir Immunotherapeutics, a company specializing in oncolytic virus immunotherapies for cancer treatment. He has held this position since June 2019, contributing to the development of innovative therapeutic approaches that leverage the natural ability of viruses to target and destroy cancer cells.12

Professional Background

• KaliVir Immunotherapeutics (2019 - Present)

  • Role: Board Member, Founder
  • Focus: Development of oncolytic virus therapies for cancer.15

• Western Oncolytics Ltd. (2012 - Present)

  • Role: Founder, CEO (from 2012) and Board Member (from 2018)
  • Focus: Immuno-oncolytic cancer therapy, including partnerships for technology licensing and fundraising efforts.23

• BiognoSYS AG (2011)

  • Role: Head of Product Development and Marketing
  • Focus: Proteomics services for various industries.13

• Holcim US Inc. (2006 - 2009)

  • Role: Strategy and Business Development, Senior Analyst.2

Education

Kurt Rote holds an MBA from the International Institute for Management Development (IMD) in Switzerland, which he completed in 2010. He also earned a Bachelor of Science in Engineering (B.S.E.) in Biomedical Engineering from Duke University, graduating between 2001 and 2004.236

Contributions to the Field

Rote's work has significantly impacted the development of cancer therapies through his leadership roles in various companies. At KaliVir, he is involved in pioneering techniques that utilize engineered viruses to enhance cancer treatment efficacy while minimizing invasive procedures. His previous experience at Western Oncolytics included pivotal fundraising and technology partnerships that have advanced the field of immunotherapy.34